Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: The double face of miR-320: cardiomyocytes-derived miR-320 deteriorated while fibroblasts-derived miR-320 protected against heart failure induced by transverse aortic constriction

Fig. 5

The different expression patterns of miR-320 were governed by Ago2. a Schematic diagram of co-culture assay. Top well, NRCFs; lower chamber, NRCMs. b NRCFs in the top chamber were photographed by fluorescence microscope after transfected with Cy3-labeled miR-320. ACTN2 staining of NRCMs in the lower chamber. Scale bar, 100 µm. c Protein expression levels of Ago2 and GAPDH in mouse hearts after TAC (left). Quantitative analysis of Ago2 protein levels after normalization to GAPDH (right). d Ago2 mRNA levels in CMs at different time points after TAC were measured by real-time PCR. Sham (n = 10), TAC-Day 3 (n = 13), TAC-Day 7 (n = 9), TAC-Day 14 (n = 11), TAC-Day 28 (n = 10), and TAC-Day 70 (n = 11). e Ago2 mRNA levels in CFs at different time points after TAC were measured by real-time PCR. Sham (n = 10), TAC-Day 3 (n = 12), TAC-Day 7 (n = 9), TAC-Day 14 (n = 11), TAC-Day 28 (n = 10), and TAC-Day 70 (n = 11). f Relative miR-320 levels in si-Ago2 treated NRCMs (left, n ≥ 3) and NRCFs (right, n ≥ 3). g Mature miR-320 levels detected by real-time PCR after actinomycin D treatment, normalization to GAPDH in NRCMs (left, n = 4) and NRCFs (right, n = 4). h Protein expression levels of Ago2 and GAPDH in NRCMs with Ang II treatment (left). Quantitative analysis of Ago2 protein levels after normalization to GAPDH (right). i MiR-320 expression levels in NRCMs with different treatments were measured by real-time PCR (n ≥ 3). j Protein expression levels of Ago2 and GAPDH in NRCFs with Ang II treatment (left). Quantitative analysis of Ago2 protein levels after normalization to GAPDH (right). k MiR-320 expression levels in NRCFs with different treatment were measured by real-time PCR (n ≥ 3). Data are expressed as mean ± SEM

Back to article page